Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1955 1
1966 1
1967 1
1968 2
1969 1
1970 2
1973 1
1975 1
1978 5
1979 1
1981 2
1982 1
1983 1
1985 1
1987 2
1988 4
1989 3
1991 3
1994 1
1998 1
1999 3
2000 6
2001 9
2002 7
2003 1
2004 5
2005 5
2006 5
2007 3
2008 8
2009 9
2010 9
2011 8
2012 2
2013 9
2014 5
2015 4
2016 1
2017 5
2018 2
2019 3
2021 4
2022 6
2023 1
2024 4
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

150 results

Results by year

Filters applied: . Clear all
Page 1
Amendment „Neue Nomenklatur zur MASLD (Metabolic Dysfunction Associated Steatotic Liver Disease; metabolische Dysfunktion assoziierte steatotische Lebererkrankung)“ zur S2k-Leitlinie „Nicht-alkoholische Fettlebererkrankung“ (v.2.0/April 2022) der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS).
Roeb E, Canbay A, Bantel H, Bojunga J, de Laffolie J, Demir M, Denzer UW, Geier A, Hofmann WP, Hudert C, Karlas T, Krawczyk M, Longerich T, Lüdde T, Roden M, Schattenberg JM, Sterneck M, Tannapfel A, Lorenz P, Tacke F; Collaborators. Roeb E, et al. Z Gastroenterol. 2024 Jul;62(7):1077-1087. doi: 10.1055/a-2309-6052. Epub 2024 Jul 8. Z Gastroenterol. 2024. PMID: 38976985 German. No abstract available.
Aktualisierte S2k-Leitlinie nicht-alkoholische Fettlebererkrankung der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – April 2022 – AWMF-Registernummer: 021–025.
Roeb E, Canbay A, Bantel H, Bojunga J, de Laffolie J, Demir M, Denzer UW, Geier A, Hofmann WP, Hudert C, Karlas T, Krawczyk M, Longerich T, Luedde T, Roden M, Schattenberg J, Sterneck M, Tannapfel A, Lorenz P, Tacke F; Collaborators:. Roeb E, et al. Z Gastroenterol. 2022 Sep;60(9):1346-1421. doi: 10.1055/a-1880-2283. Epub 2022 Sep 13. Z Gastroenterol. 2022. PMID: 36100202 Free article. German. No abstract available.
The role of everolimus in liver transplantation.
Ganschow R, Pollok JM, Jankofsky M, Junge G. Ganschow R, et al. Clin Exp Gastroenterol. 2014 Sep 2;7:329-43. doi: 10.2147/CEG.S41780. eCollection 2014. Clin Exp Gastroenterol. 2014. PMID: 25214801 Free PMC article. Review.
Everolimus in pediatric transplantation.
Pape L, Ganschow R, Ahlenstiel T. Pape L, et al. Among authors: ganschow r. Curr Opin Organ Transplant. 2012 Oct;17(5):515-9. doi: 10.1097/MOT.0b013e328356b080. Curr Opin Organ Transplant. 2012. PMID: 22890040 Review.
Mutations in CRLF1 cause familial achalasia.
Busch A, Žarković M, Lowe C, Jankofsky M, Ganschow R, Buers I, Kurth I, Reutter H, Rutsch F, Hübner CA. Busch A, et al. Among authors: ganschow r. Clin Genet. 2017 Jul;92(1):104-108. doi: 10.1111/cge.12953. Epub 2017 Mar 15. Clin Genet. 2017. PMID: 27976805
Murine catalase phenotypes.
Ganschow RE, Schimke RT. Ganschow RE, et al. Biochem Genet. 1970 Feb;4(1):157-67. doi: 10.1007/BF00484027. Biochem Genet. 1970. PMID: 5462766 No abstract available.
150 results